

2nd Swedish Medicinal Chemistry Symposium

September 25-26, 2019, Stockholm, Sweden

| Progr | am en |
|-------------------------|--|
| riogi | |
| Wednesday, September 25 | |
| 08.15 | Registration |
| 08.45 | Opening remarks – House keeping |
| 09.00 | Plenary Lecture 1: Application of Al algorithms in the daily life of Medicinal Chemists – Status 2019 |
| | Werngard Czechtizky, AstraZeneca, Mölndal |
| 09.45 | Discovery of NUDIX and Glycosylase inhibitors |
| | Martin Scobie, Karolinska Institutet, Stockholm |
| 10.15 | Break |
| 10.45 | From screening to optimized lead on an "undruggable" aquaporin target for diabetes Thomas Brimert, Red Glead Discovery, Lund |
| 11.15 | Chemical synthesis of membrane-associated proteins: promising method for drug discovery |
| | Alesia Tietze, University of Gothenburg |
| 11.45 | Lunch |
| 12.45 | Plenary Lecture 2: Elucidation of autophagy by chemical genetic approaches |
| | Yaowen Wu, Umeå University |
| 13.30 | Peptide-based drug discovery – new methods and applications Anja Sandström, Uppsala University |
| 14.00 | Accelerating drug discovery through automation |
| | Michael Kossenjans, AstraZeneca, Mölndal |
| 14.30 | Break |
| 15.00 | Arvid Carlsson memorial |
| 15.30 | Flash Poster Presentations |
| 16.30- | Cocktails & Poster Session |
| 18.00 | |
| Thursday, September 26 | |
| 08.45 | House keeping |
| 09.00 | The Swedish Pharmaceutical Society 2019 Medicinal Chemistry Award |
| 09.15 | The 2019 Medicinal Chemistry Prize Lecture |
| 09.45 | Discovery of Mycobacterial Tolerance Inhibitors – Chemical disarming of drug resistance in Mycobacterium tuberculosis |
| | Fredrik Almqvist, Umeå University |
| 10.15 | Break |
| 10.45 | Title to be announced |
| 11.15 | Ulrika Yngve, ScilifeLab, Uppsala University Directed evolution in drug discovery |
| 11.15 | Michael Gossing, AstraZeneca, Mölndal |
| 11.45 | Lunch |
| 12.45 | Plenary Lecture 3: Title to be announced |
| | Mikael Akke, Lund University |
| 13.30 | Poster Session Control of the Contro |
| 14.00 | Exploring the prevalence, function and regulation of short linear motif-based interactions |
| 14.20 | Ylva Ivarsson, Uppsala University |
| 14.30 | Break Discovery of AZDEZ18, a payol E lineavygoods activation aretoic (ELAD) inhibitor |
| 15.00 | Discovery of AZD5718, a novel 5-lipoxygenase activating protein (FLAP) inhibitor Malin Lemurell, AstraZeneca, Mölndal |
| 15.30 | Resin-acid derivatives as potassium channel openers and potential antiepileptic drugs |
| | Fredrik Elinder, Linköping University |
| 16.00- | |
| 16.30 | Concluding Remarks – End of Meeting |